Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: Omeros is a clinical-stage biopharmaceutical company focused on developing therapeutics for immunologic disorders, complement-mediated diseases, and addictive disorders. Key programs include narsoplimab (MASP-2 inhibitor for TA-TMA), zaltenibart (MASP-3 inhibitor for PNH and C3G), and OMS527 (PDE7 inhibitor for cocaine use disorder). The company divested its commercial product OMIDRIA in 2021, which is now reported as discontinued operations.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Loss (Continuing Ops) | $(65,125) | $(44,294) | $(108,975) | $(83,977) |
| Net Income (Discontinued Ops) | $9,084 | $7,000 | $15,750 | $12,982 |
| Total Net Loss | $(56,041) | $(37,294) | $(93,225) | $(70,995) |
| Research & Development Expenses | $45,349 | $29,639 | $72,119 | $54,249 |
| Selling, General & Admin Expenses | $13,808 | $11,260 | $26,072 | $22,363 |
| Interest Expense | $9,215 | $7,932 | $17,446 | $15,865 |
| Cash & Cash Equivalents (End of Period) | $2,120 | $6,603 | $2,120 | $6,603 |
| Short-term Investments | $156,792 | $164,743 | $156,792 | $164,743 |
| Total Liquidity (Cash + ST Inv) | $158,912 | $171,346 | $158,912 | $171,346 |
| Long-term Debt (Net) | $94,506 | $0 | $94,506 | $0 |
| Convertible Senior Notes (Net) | $96,888 | $213,155 | $96,888 | $213,155 |
| OMIDRIA Royalty Obligation | $231,757 | $125,126 | $231,757 | $125,126 |
Material Changes vs. Prior Period
- Debt Restructuring: On June 3, 2024, the company entered a Credit Agreement for a $67.1 million initial term loan and used proceeds plus $21.2 million cash to repurchase $118.1 million of its 2026 Convertible Senior Notes. This reduced the principal balance of the 2026 Notes by approximately 55%.
- Royalty Monetization: In February 2024, Omeros sold an expanded interest in future OMIDRIA royalties to DRI Healthcare Acquisition LP for $115.5 million, increasing the OMIDRIA royalty obligation significantly.
- Operating Expenses: R&D expenses increased by $15.7 million (Q2) and $17.9 million (YTD) compared to the prior year, driven by narsoplimab drug substance manufacturing costs ($17.6 million charge in Q2) and zaltenibart clinical trial costs.
- Cash Flow: Net cash used in operating activities was $87.8 million for the six months ended June 30, 2024, compared to cash provided of $142.2 million in the prior year period. The prior year included a $200 million milestone payment from the OMIDRIA sale.
- Share Repurchases: The company repurchased 3.2 million shares for $11.9 million in Q1 2024. The share repurchase program was terminated upon execution of the new Credit Agreement in June 2024.
Guidance, Outlook, and Risks
- Regulatory Outlook (Narsoplimab): The company is in ongoing discussions with the FDA regarding the resubmission of the Biologics License Application (BLA) for narsoplimab in TA-TMA. Management cannot currently estimate the timing of resubmission or approval. A $25 million delayed draw term loan is available if FDA approval is received by June 3, 2025.
- Clinical Pipeline: Phase 3 trials for zaltenibart in PNH are targeted to begin in late 2024. Phase 3 for C3G is targeted for Q1 2025. Toxicology studies for OMS527 (cocaine use disorder) are expected to complete in late 2024.
- Liquidity: As of June 30, 2024, the company held $158.9 million in cash and short-term investments. Management expects to fund operations and service debt for at least the next 12 months. A covenant requires maintaining at least $25.0 million in unrestricted cash.
- Risks:
- Debt Covenants: The new Credit Agreement restricts operating flexibility, including limitations on further debt, asset sales, and stock repurchases. Default could lead to acceleration of debt and loss of assets, including intellectual property.
- Regulatory Uncertainty: No guarantee exists that the FDA will accept the proposed analysis plan for narsoplimab or that approval will be granted.
- Capital Needs: The company has not established an ongoing revenue source sufficient to cover costs and may need to raise additional capital.
Investor Verification Checklist
- Debt Structure: Verify the terms of the new $67.1 million term loan, specifically the interest rate (SOFR + 8.75%), prepayment penalties, and the $25 million cash covenant.
- 2026 Notes Status: Confirm the remaining principal balance of the 2026 Convertible Senior Notes ($97.9 million) and the impact of the capped call transactions on potential dilution.
- OMIDRIA Royalty Obligation: Review the valuation assumptions for the $231.8 million royalty obligation and the impact of the DRI Amendment on future cash flows.
- Narsoplimab Timeline: Monitor communications regarding the FDA's requirements for the BLA resubmission and the potential impact on the $25 million delayed draw loan.
- Burn Rate: Assess the sustainability of the current cash position given the $87.8 million operating cash burn in the first half of 2024 and the one-time nature of the Q2 manufacturing charge.